ELCC 2026: vídeos e entrevistas
23 vídeos do ELCC 2026 publicados por Targeted Oncology, VJOncology, ecancer. Atualizado em 20/11/2026.
Current and emerging HER2-targeted therapies in NSCLCVJOncology · 27/07/2026 · 2:43 · apoio da indústria
Neoadjuvant vs perioperative immunotherapy in resectable NSCLCVJOncology · 27/07/2026 · 1:10 · apoio da indústria
Opportunities and challenges in the exon 20 insertion space in lung cancerVJOncology · 27/07/2026 · 1:47 · apoio da indústria
Optimal sequencing of EGFR-targeted therapies for NSCLCVJOncology · 27/07/2026 · 2:04 · apoio da indústria
Updated results from PALOMA-2: first-line subcutaneous amivantamab plus lazertinib in NSCLCVJOncology · 27/07/2026 · 2:19 · apoio da indústria
Local consolidative therapy with osimertinib: NorthStar trial background and secondary analysisVJOncology · 27/07/2026 · 1:46 · apoio da indústria
Beamion LUNG-1: zongertinib in treatment-naïve HER2-mutant NSCLC and in those with brain metastasesVJOncology · 27/07/2026 · 1:10 · apoio da indústria
Calderasib, a novel KRAS G12C-off inhibitor in NSCLC: insights from the KANDLELIT-001 trialVJOncology · 27/07/2026 · 1:47 · apoio da indústria
Toxicity management with bispecific T-cell engagers in lung cancerVJOncology · 27/07/2026 · 1:09 · apoio da indústria
Findings from a global physician survey examining treatment decisions in EGFRm NSCLCVJOncology · 22/07/2026 · 2:37 · apoio da indústria
Treatment sequencing in EGFR-mutated NSCLCVJOncology · 22/07/2026 · 2:25 · apoio da indústria
Targeted therapy options by BRAF mutation class in lung cancerVJOncology · 22/07/2026 · 2:07 · apoio da indústria
How does disease biology vary across BRAF mutation classes in lung cancer?VJOncology · 22/07/2026 · 3:08 · apoio da indústria
Tarlatamab: a promising new therapy for SCLC?VJOncology · 22/07/2026 · 1:04 · apoio da indústria
DeLLphi-312: tarlatamab with chemoimmunotherapy for first-line treatment of ES-SCLCVJOncology · 22/07/2026 · 2:02 · apoio da indústria
Cracking the code: Bispecific immunotherapy in small cell lung cancerecancer · 08/05/2026 · 6:15 · apoio da indústria
Dr. Offin and Dr. Schoenfeld on New Lung Cancer AdvancesTargeted Oncology · 15/04/2026 · 10:54 · apoio da indústria
The Biggest Unmet Needs in #LungCancerTargeted Oncology · 13/04/2026 · 1:04 · apoio da indústria
ELCC 2026: TOP Study, Sac-TMT, and the Future of EGFR-Mutant NSCLCTargeted Oncology · 09/04/2026 · 7:45 · apoio da indústria
Cardiac comorbidities in lung cancer: bridging the evidence gap in clinical practiceVJOncology · 27/03/2026 · 4:24 · apoio da indústria
Cardiac comorbidities in lung cancer: key challenges and approaching treatment decision-makingVJOncology · 27/03/2026 · 2:12 · apoio da indústria
How pathologic response shapes post-operative decision-making in resectable NSCLCVJOncology · 27/03/2026 · 1:03 · apoio da indústria
Is major pathologic response the best surrogate endpoint for neoadjuvant trials in NSCLC?VJOncology · 27/03/2026 · 1:03 · apoio da indústria